SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACMI - Accumed Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cisco who wrote (957)1/6/1998 10:40:00 AM
From: Sigmund  Read Replies (1) of 1894
 
Stamford Conn....active at night.

Yes NeoPath went in without any real data I think maybe 50 slides or something pathetic like that so it is no surprise that they got turned down. I don't think they have anyone on staff with any FDA experience.

Yes certainly their direct competitors may be hurt either way and this is reflected in the prices of their stocks.

Yes I agree that ACMI probably wins either way...why I bought in.

But I still think that overall, a very nervous FDA on cytology is not good for anyone in the sector. How about the Kirby-Bauer machine? It requires FDA approval. Do you think the 510(k) short-cut will fly if NeoPath gets turned down? I very much doubt it. It is a different committee but still there would be pressure on/in the FDA to be "even handed".
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News